AR
Arcturus Therapeutics Holdings Inc.
ARCT · NASDAQ
$14.74 -4.35% (-$0.67)
1M +96.01%
Market Cap $419.0M
P/E Ratio -
Div. Yield -
ROE 46.54%
Piotroski F-Score Weak
1/9Valuation
39 /100
Fair P/B 2.44x
P/S 17.60x
PEG N/A
Growth
0 /100
Declining Book val. growth 7.49%
Rev. growth 31.13%
FCF growth N/A
Profitability
20 /100
Weak FCF margin 306.91%
Op. margin 433.36%
Gross margin 83.19%
Quality
1 /100
Poor Asset turnover 0.11x
ROA 41.58%
ROIC 52.96%
Debt
100 /100
Low Current ratio 5.88x
Debt/Equity 0.13x
Net debt/EBITDA N/A
Stability
18 /100
Unstable Profitable years 0
EPS volatility 220.78%
Beta 2.27x
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na ARCT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Joseph E. Payne
Employees
109
Headquarters
San Diego
Nadcházející události
09 LIS
Earnings
Upcoming earnings report